Clinical Trial Update: Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the combination of venetoclax and decitabine in patients aged 60 to 74 with newly diagnosed acute myeloid leukemia eligible for allogene…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Dacogen (decitabine)
• Venclexta (venetoclax)

Snippet

Sponsor: Gruppo Italiano Trapianto di Midollo Osseo | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING